NCODA supports the principle that medications should improve the patient’s quality of life while simultaneously treating the disease. We will continue to follow these developments as our patient-centered approach reaches the heart of clinical trial design in the oncology space. Article here

Former NCODA Keynote Speaker Doug Collins (R-Ga.) reintroduced legislation that would increase transparency in drug pricing while lowering costs for patients. Updates on H.R. 1035 The Prescription Drug Pricing Transparency Act and H.R. 1034 The Phair Pricing Act can be found here at NCODA as we continue to advocate for cancer patients. Read More

Lawmakers are pushing forward legislation that would allow biosimilar and generic competition to enter the market sooner, suggesting that this change will drive down drug prices for US patients. Read more

Recent meta-analysis reveals low-dose aspirin may reduce the risk of certain cancers. Read more here:

Health insurer Anthem is launching its in-house pharmacy benefit manager IngenioRx nine months earlier than planned in the second quarter of 2019. 

Anthem said Wednesday that it will exercise its rights to terminate its current PBM contract with Express Scripts on March 1 before it expires at the end of the year, due to Cigna Corp.’s acquisition of Express Scripts late last year. It will then begin transitioning its plan members to the new PBM over 12 months. Read more of this article HERE.